Lupin Limited, a global pharmaceutical company, has achieved a significant milestone by securing an S&P Global ESG Score of 91 for 2025. This score places the company among a select group of pharmaceutical organizations that have crossed the 90-point threshold, far exceeding the industry average score of 28. The company’s ESG rating has shown a remarkable improvement, rising from 17 in 2021, which is one of the fastest improvements recorded in the sector.
According to Ramesh Swaminathan, Executive Director and Global CFO of Lupin, this achievement reflects the company’s unwavering commitment to sustainability and its purpose-led strategy. The company has made significant progress across environmental, social, and governance pillars, aligning with global standards for sustainable business practices. Lupin has made notable advances in renewable energy adoption, reduction of carbon emissions, and attainment of water-positive operations. The company has also strengthened its social initiatives, including employee well-being, diversity and inclusion, and community healthcare outreach.
In terms of governance, Lupin has implemented stronger transparency frameworks, enhanced ethical practices, and introduced board-level oversight mechanisms to address ESG-related risks and opportunities. The company operates in over 100 markets and maintains 15 manufacturing sites and seven research centers worldwide. With this improved ESG score, Lupin has reinforced its commitment to responsible growth and has positioned itself as a global leader in sustainable pharmaceutical practices.
The achievement is a testament to Lupin’s efforts to embed sustainability within its business operations while expanding its offerings across therapeutic areas. The company’s leadership in ESG performance is expected to have a positive impact on its stakeholders, including patients, communities, and investors. With its strong commitment to sustainability, Lupin is well-positioned to drive long-term growth and success while making a positive contribution to the environment and society. Overall, Lupin’s achievement is a significant milestone in the pharmaceutical industry, demonstrating the company’s dedication to responsible and sustainable business practices.